688298 Zhejiang Orient Gene Biotech
- 29.56
- +0.04+0.14%
Zhejiang Orient Gene Biotech News
What Zhejiang Orient Gene Biotech Co.,Ltd's (SHSE:688298) P/S Is Not Telling You
With a median price-to-sales (or "P/S") ratio of close to 7x in the Biotechs industry in China, you could be forgiven for feeling indifferent about Zhejiang Orient Gene Biotech Co.,Ltd's (SHSE:688298
Oriental Biotech (688298.SH): Net loss of 67.3535 million yuan in the first quarter
Gelonghui, April 29丨Oriental Biotech (688298.SH) released its report for the first quarter of 2024, achieving operating income of 183 million yuan, a year-on-year decrease of 51.36%; net profit attributable to shareholders of listed companies - 67.3535 million yuan, net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 109 million yuan, and basic earnings per share - 0.33 yuan.
Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it might be obvious
Oriental Biotech (688298.SH): Stock repurchases have not been implemented
Gelonghui March 1 | Oriental Biotech (688298.SH) announced that as of the disclosure date of this announcement, the company had not implemented a stock repurchase.
Oriental Biotech (688298.SH): Net loss of 404 million yuan in 2023
Gelonghui, Feb. 28: Oriental Biotech (688298.SH) announced the 2023 Annual Results Report. In 2023, the company achieved total operating revenue of 824.128 million yuan, a decrease of 90.60% over the previous year; net profit attributable to the owner of the parent company after deducting non-recurring profit and loss - RMB 404.472,500, a decrease of 119.36% over the previous year.
Express News | Oriental Biotech: Plans to buy back shares for 50 million yuan to 100 million yuan
Express News | More than 30 listed companies announced plans to repurchase or increase their holdings by up to 100 million yuan after the market and announced that the controlling shareholders of Tongwei Co., Ltd. intend to increase their holdings by up to 2 billion yua
Express News | Oriental Biotech: The actual controller proposed to buy back shares for 50 million yuan to 100 million yuan
Oriental Biotech (688298.SH): Pre-loss of 380 million yuan in 2023
Gelonghui, January 30丨Oriental Biotech (688298.SH) announced the 2023 annual results forecast loss announcement. According to preliminary estimates by the finance department, it is expected to achieve net profit of 38,0000 million yuan in 2023, which will result in a loss. At the same time, compared with the net profit of 206,771.43 million yuan (statutory disclosure data), the net profit attributable to owners of the parent company in the previous year is expected to decrease by 244,7714,300 yuan, a year-on-year decrease of 118.38%. According to preliminary estimates by the finance department, it is expected that deductions attributable to the owners of the parent company will be achieved in 2023
[BT Financial Report Momentary Analysis] Oriental Biotech's 2023 Quarterly Report: Performance Changes and Future Prospects in the Face of Challenges
Oriental Biotech (stock code: 688298), as a listed company focusing on the in vitro diagnosis industry, its 2023 three-quarter report data shows the company's latest financial situation in the medical device segment. As an important component of laboratory medicine, Oriental Biotech's market size continues to grow, and it is expected that the global in vitro diagnosis market will maintain a steady growth trend. In terms of assets and liabilities, Oriental Biotech's total assets decreased from 10.704 billion yuan at the end of the previous year to 9.17 billion yuan at the end of the reporting period. Total liabilities also fell from 2,381 billion yuan at the end of the previous year to 1,243 billion yuan, net capital
Oriental Biotech (688298.SH) has obtained registration certificates for various medical devices
Oriental Biotech (688298.SH) issued an announcement. The company's holding subsidiary, Nanjing Changjian Biotechnology Co., Ltd. (simplified...
Zhejiang Orient Gene Obtains Veterinary GMP Certificate, Production License
Zhejiang Orient Gene Biotech (SHA:688298) has received the veterinary drug GMP certificate and veterinary drug production license from the Zhejiang Provincial Department of Agriculture and Rural Affai
Oriental Biology (688298.SH): Obtained “Veterinary Drug GMP Certificate” and “Veterinary Drug Production License”
On January 5, Gelonghui (688298.SH) announced that the company recently obtained the “Veterinary Drug GMP Certificate” and “Veterinary Drug Production License” issued by the Zhejiang Provincial Department of Agriculture and Rural Affairs. The company's approved immunological diagnostic product (Class B) production line can be used to produce canine parvovirus rapid diagnostic test strips (CPV-Ag), canine coronavirus rapid diagnostic test strips (CCV-Ag), canine distemper virus rapid diagnostic strips (CDV-Ag), canine influenza virus rapid diagnostic tests (CiV-Ag), canine adenovirus rapid diagnostic tests (CAV-Ag), and cat plague virus
Oriental Biotech (688298.SH): The subsidiary plans to acquire 51.25% of Hangzhou Laihe shares for 69.1932 million yuan
Gelonghui, December 29丨Oriental Biotech (688298.SH) announced that its wholly-owned subsidiary Hainan Qikang Investment Co., Ltd. plans to acquire 51.2542% of Hangzhou Laihe's shares with its own capital of 69.193.16 million yuan; after the completion of this share acquisition, Hangzhou Laihe will become a subsidiary of Hainan Qikang Holdings. The target company mainly develops, produces and operates the following products: drug (urine, saliva, hair) testing; inflammation (hs-CRP, PCT, CRP-SAA, PCR-IL6, etc.) testing; cardiac marker (cTNL, NT-probnp, CMA) testing
Oriental Biology (688298.SH): Controlling shareholders Anji Fulanglai and Fangshi Holdings voluntarily promise not to reduce their holdings of the company's shares within 18 months
On December 6, Gelonghui (688298.SH) announced that based on confidence in the company's future development prospects and recognition of the company's values, and at the same time, to support the company's continuous, healthy and stable development and reasonable reflection of internal value, the interests of investors are protected. Anji Fulanglai, the controlling shareholders of Oriental Biotech, and Fangshi Holdings voluntarily promised: “Within 18 months from now (that is, December 6, 2023 to June 5, 2025), we will not reduce our holdings of Oriental Biotech's shares directly held by the Company in any way, including the transfer of shares directly held by the Company during the commitment period due to capital accumulation, distribution of stock dividends, stock allocations,
A Look At The Intrinsic Value Of Zhejiang Orient Gene Biotech Co.,Ltd (SHSE:688298)
Key Insights Zhejiang Orient Gene BiotechLtd's estimated fair value is CN¥34.32 based on Dividend Discount Model Current share price of CN¥40.15 suggests Zhejiang Orient Gene BiotechLtd is potential
Oriental Biology (688298.SH): Alzheimer's disease-related testing products are in the development stage
Gelonghui, November 27|Oriental Biology (688298.SH) said on an interactive platform that the company and its subsidiary's Mycoplasma pneumoniae POCT rapid detection reagent and nucleic acid detection reagent have obtained EU CE certification. The subsidiary's Mycoplasma pneumoniae POCT rapid test reagent holds three types of domestic medical device certificates. For details, see the regular reports disclosed by the company over the years; the company's Alzheimer's disease-related testing products are in the development stage.
Oriental Biology (688298.SH): Net loss of 72.384 million yuan in the first three quarters
On October 30, Gelonghui (688298.SH) released its report for the third quarter of 2023. The company achieved operating income of 652 million yuan in the first three quarters, a decrease of 91.70% over the previous year; net loss attributable to shareholders of listed companies of 72.384 million yuan; and net loss attributable to shareholders of listed companies to deduct non-recurring profits and losses of 105 million yuan.
Health Check: How Prudently Does Zhejiang Orient Gene Biotech (SHSE:688298) Use Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
[Instant Analysis of BT Financial Report] Oriental Biotech 2023 Interim Report Analysis: Facing challenges, responding positively, business conditions to be seen
Oriental Biology (stock code: 688298) is a company focusing on the in vitro diagnosis industry. Its industry is the in vitro diagnosis industry under the medical device industry. In vitro diagnostic products mainly include diagnostic equipment and diagnostic reagents, among which diagnostic reagents dominate the entire industry. The size of the global in vitro diagnostic market continues to grow, and is expected to grow at a compound annual growth rate of around 6% in the future. As a member of the in vitro diagnostic industry, Dongfang Biotech is expected to benefit from the development trend of the industry. However, according to Dongfang Biotech's 2023 interim report, the company faced a sales business that basically removed COVID-19 testing products during this reporting period, resulting in
Analysis
Price Target
No Data
